Your browser doesn't support javascript.
loading
Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
Girard, P M; Antinori, A; Arribas, J R; Ripamonti, D; Bicer, C; Netzle-Sveine, B; Hadacek, B; Moecklinghoff, C.
Affiliation
  • Girard PM; Department of Infectious and Tropical Diseases, Hôpital Saint-Antoine, AP-HP, INSERM UMR S 1136, Paris, France.
  • Antinori A; National Institute for Infectious Diseases, L. Spallanzani IRCCS, Rome, Italy.
  • Arribas JR; Hospital University La Paz, IdiPAZ, Madrid, Spain.
  • Ripamonti D; University Hospital, Bergamo, Italy.
  • Bicer C; Biostatistics, Janssen R&D, Beerse, Belgium.
  • Netzle-Sveine B; Janssen EMEA, Issy-les-Moulineaux, France.
  • Hadacek B; Janssen EMEA, Issy-les-Moulineaux, France.
  • Moecklinghoff C; Janssen EMEA, Neuss, Germany.
HIV Med ; 18(1): 5-12, 2017 01.
Article in En | MEDLINE | ID: mdl-27279571
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Reverse Transcriptase Inhibitors / Ritonavir / Anti-HIV Agents / Antiretroviral Therapy, Highly Active / Darunavir Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: HIV Med Year: 2017 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Reverse Transcriptase Inhibitors / Ritonavir / Anti-HIV Agents / Antiretroviral Therapy, Highly Active / Darunavir Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: HIV Med Year: 2017 Document type: Article